Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Kerros, Céline ^a   Cavey, Thibault ^a   Sola, Brigitte ^a   Jauzac, Philippe ^a   Allouche, Stéphane ^a  

^a UNIVERSITÉ DE CAEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BOVINE SERUM ALBUMIN; COMPLEMENTARY DNA; DIPRENORPHINE; ETHYLKETAZOCINE; G PROTEIN COUPLED RECEPTOR; IODINE 125; LEVORPHANOL; LIPOCORTIN 5; MORPHINE; OCTREOTIDE; OPIATE AGONIST; OPIATE RECEPTOR; PROPIDIUM IODIDE; RADIOLIGAND; RECEPTOR SUBTYPE; RNA; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TRITIUM; MESSENGER RNA; SOMATOSTATIN;

APOPTOSIS; ARTICLE; BINDING ASSAY; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA CONTENT; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIGAND BINDING; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; WESTERN BLOTTING; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; HUMANS; MULTIPLE MYELOMA; RECEPTORS, OPIOID; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 67650723700     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-77     Document Type: Article

References (54)

1. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. H Yasui T Hideshima PG Richardson KC Anderson, Br J Haematol 2006 132 4 385 397 16412014 (Pubitemid 43381614)
2. Current therapy for multiple myeloma. SV Rajkumar MA Gertz RA Kyle PR Greipp, Mayo Clin Proc 2002 77 8 813 822 10.4065/77.8.813 12173715 (Pubitemid 34851268)
3. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. T Hideshima KC Anderson, Nat Rev Cancer 2002 2 12 927 937 10.1038/nrc952 12459731
4. New drugs for treatment of multiple myeloma. B Bruno M Rotta L Giaccone M Massaia A Bertola A Palumbo M Boccadoro, Lancet Oncol 2004 5 7 430 442 10.1016/S1470-2045(04)01511-6 15231250
5. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Y Taniyama T Suzuki Y Mikami T Moriya S Satomi H Sasano, Endocr J 2005 52 5 605 611 10.1507/endocrj.52.605 16284440
6. Somatostatin and its receptor family. YC Patel, Front Neuroendocrinol 1999 20 3 157 198 10.1006/frne.1999.0183 10433861
7. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. JC Reubi JC Schaer JA Laissue B Waser, Metabolism 1996 45 8 Suppl 1 39 41 10.1016/S0026-0495(96)90077-3 8769377
8. In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. JC Reubi B Waser U Horisberger E Krenning SW Lamberts JO Gebbers P Gersbach JA Laissue, Blood 1993 82 7 2143 2151 8400264 (Pubitemid 23293998)
9. Somatostatin receptor distribution and function in immune system. D Ferone PM van Hagen C Semino VA Dalm A Barreca A Colao SW Lamberts F Minuto LJ Hofland, Dig Liver Dis 2004 36 Suppl 1 S68 77 10.1016/j.dld.2003.11.020 15077914
10. Expression of somatostatin receptor subtypes in human brain tumors. A Dutour U Kumar R Panetta L Ouafik F Fina R Sasi YC Patel, Int J Cancer 1998 76 5 620 627 10.1002/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.0.CO;2-S 9610716 (Pubitemid 28243931)
11. Oncological applications of somatostatin analogues. AV Schally, Cancer Res 1988 48 24 Pt 1 6977 6985 2903792 (Pubitemid 19013968)
12. Rationale for the use of somatostatin analogs as antitumor agents. C Susini L Buscail, Ann Oncol 2006 17 12 1733 1742 10.1093/annonc/mdl105 16801334
13. Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets. EG Lichtenauer-Kaligis VA Dalm SP Oomen DM Mooij PM van Hagen SW Lamberts LJ Hofland, Eur J Endocrinol 2004 150 4 565 577 10.1530/eje.0.1500565 15080788
14. Signal transduction of somatostatin in human B lymphoblasts. D Rosskopf M Schurks I Manthey M Joisten S Busch W Siffert, Am J Physiol Cell Physiol 2003 284 1 C179 190 12388115
15. Potential indications for somatostatin analogues: immune system and limphoproliferative disorders. D Ferone E Resmini M Boschetti M Arvigo V Albanese E Ceresola R Pivonello M Albertelli F Bianchi M Giusti, J Endocrinol Invest 2005 28 11 Suppl International 111 117 16625859
16. Opioid-somatostatin interactions in regulating cancer cell growth. A Hatzoglou M Kampa E Castanas, Front Biosci 2005 10 244 256 10.2741/1524 15574365 (Pubitemid 40552762)
17. Dimerization of G protein-coupled receptors: New avenues for somatostatin receptor signalling, control and functioning. M Duran-Prado MM Malagon F Gracia-Navarro JP Castano, Mol Cell Endocrinol 2008 286 12 63 68 10.1016/j.mce.2007.12.006 18242821
18. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. P Chomczynski N Sacchi, Anal Biochem 1987 162 1 156 159 10.1016/0003-2697(87)90021-2 2440339 (Pubitemid 17064313)
19. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. MC Zatelli D Piccin A Bottoni MR Ambrosio A Margutti R Padovani M Scanarini JE Taylor MD Culler L Cavazzini, J Clin Endocrinol Metab 2004 89 10 5181 5188 10.1210/jc.2003-031954 15472224
20. Primer3 on the WWW for general users and for biologist programmers. S Rozen H Skaletsky, Methods Mol Biol 2000 132 365 386 10547847
21. Identification, characterization, and biological activity of somatostatin receptors in human neuroblastoma cell lines. M Maggi E Baldi G Finetti F Franceschelli A Brocchi R Lanzillotti M Serio MG Camboni CJ Thiele, Cancer Res 1994 54 1 124 133 8261433 (Pubitemid 24042099)
22. Biology of somatostatin in breast cancer. HL Watt G Kharmate U Kumar, Mol Cell Endocrinol 2008 286 12 251 261 10.1016/j.mce.2008.01.006 18308465
23. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. M Blaker M Schmitz A Gocht S Burghardt M Schulz DC Broring A Pace H Greten A De Weerth, J Hepatol 2004 41 1 112 118 10.1016/j.jhep.2004.03.018 15246216
24. Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. L Pan J Xu R Yu MM Xu YX Pan GW Pasternak, Neuroscience 2005 133 1 209 220 10.1016/j.neuroscience.2004. 12.033 15893644
25. Opioid receptors in human neuroblastoma SH-SY5Y cells: evidence for distinct morphine (mu) and enkephalin (delta) binding sites. SM Kazmi RK Mishra, Biochem Biophys Res Commun 1986 137 2 813 820 10.1016/0006-291X(86)91152-6 3015131 (Pubitemid 16044460)
26. SK-N-BE: a human neuroblastoma cell line containing two subtypes of delta-opioid receptors. J Polastron M Mur H Mazarguil A Puget JC Meunier P Jauzac, J Neurochem 1994 62 3 898 906 8113811
27. Pharmacological delta1- and delta2-opioid receptor subtypes in the human neuroblastoma cell line SK-N-BE: no evidence for distinct molecular entities. S Allouche A Hasbi V Ferey B Sola P Jauzac J Polastron, Biochem Pharmacol 2000 59 8 915 925 10.1016/S0006-2952(99)00404-9 10692556
28. The kappa-opioid receptor from human placenta: hydrodynamic characteristics and evidence for its association with a G protein. G Porthe B Frances B Verrier J Cros JC Meunier, Life Sci 1988 43 6 559 567 10.1016/0024-3205(88)90159-2 2841553
29. Opioid receptor blockade increases the number of lymphocytes without altering T cell response in draining lymph nodes in vivo. M Jaume S Laffont E Chapey C Blanpied G Dietrich, J Neuroimmunol 2007 188 12 95 102 10.1016/j.jneuroim.2007.06.013 17617474
30. Opioids as modulators of cell death and survival unraveling mechanisms and revealing new indications. I Tegeder G Geisslinger, Pharmacol Rev 2004 56 3 351 369 10.1124/pr.56.3.2 15317908
31. Fas-mediated cell death promoted by opioids. D Yin RA Mufson R Wang Y Shi, Nature 1999 397 6716 218 10.1038/16612 9930695
32. Apoptogenic effect of fentanyl on freshly isolated peripheral blood lymphocytes. G Delogu S Moretti A Antonucci M Marandola G Tellan P Sale R Carnevali G Famularo, J Trauma 2004 57 1 75 81 10.1097/01.TA.0000075349.66640.3E 15284552 (Pubitemid 39079233)
33. Morphine induces apoptosis in murine thymocytes in vivo but not in vitro: involvement of both opiate and glucocorticoid receptors. BA Fuchs SB Pruett, J Pharmacol Exp Ther 1993 266 1 417 423 8392561 (Pubitemid 23315677)
34. Somatostatin receptor subtypes: targeting functional and therapeutic specificity. MD Culler JE Taylor JP Moreau, Ann Endocrinol (Paris) 2002 63 2 Pt 3 2S5 12 12037501
35. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. K Sharma YC Patel CB Srikant, Mol Endocrinol 1996 10 12 1688 1696 10.1210/me.10.12.1688 8961277
36. Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways. J Guillermet-Guibert N Saint-Laurent L Davenne P Rochaix O Cuvillier MD Culler L Pradayrol L Buscail C Susini C Bousquet, Cell Death Differ 2007 14 2 197 208 10.1038/sj.cdd.4401939 16645635
37. Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. HL Liu L Huo L Wang, Acta Pharmacol Sin 2004 25 10 1380 1386 15456543 (Pubitemid 39361813)
38. Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. P Luciani S Gelmini E Ferrante A Lania S Benvenuti S Baglioni G Mantovani I Cellai F Ammannati A Spada, J Clin Endocrinol Metab 2005 90 11 6156 6161 10.1210/jc.2005-0633 16091489
39. Multiple myeloma: evolving genetic events and host interactions. WM Kuehl PL Bergsagel, Nat Rev Cancer 2002 2 3 175 187 10.1038/nrc746 11990854 (Pubitemid 37328787)
40. Somatostatin receptors. LN Moller CE Stidsen B Hartmann JJ Holst, Biochim Biophys Acta 2003 1616 1 1 84 10.1016/S0005-2736(03)00235-9 14507421
41. The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. P Georgii-Hemming T Stromberg ET Janson M Stridsberg HJ Wiklund K Nilsson, Blood 1999 93 5 1724 1731 10029602 (Pubitemid 29102501)
42. Novel modalities of somatostatin actions. S Krantic I Goddard A Saveanu N Giannetti J Fombonne A Cardoso P Jaquet A Enjalbert, Eur J Endocrinol 2004 151 6 643 655 10.1530/eje.0.1510643 15588232
43. Neuroendocrine tumors of the gastro-entero-pancreatic system. S Massironi V Sciola M Peracchi C Ciafardini MP Spampatti D Conte, World J Gastroenterol 2008 14 35 5377 5384 10.3748/wjg.14.5377 18803349
44. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. J Cebon M Findlay C Hargreaves M Stockler P Thompson M Boyer S Roberts A Poon AM Scott V Kalff, Br J Cancer 2006 95 7 853 861 10.1038/sj.bjc.6603325 16953241
45. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. L Buscail JP Esteve N Saint-Laurent V Bertrand T Reisine AM O'Carroll GI Bell AV Schally N Vaysse C Susini, Proc Natl Acad Sci USA 1995 92 5 1580 1584 7878022 10.1073/pnas.92.5.1580
46. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. C Liebmann, Cell Signal 2001 13 11 777 785 10.1016/S0898-6568(01)00192-9 11583913
47. Antitumor effects of somatostatin. S Pyronnet C Bousquet S Najib R Azar H Laklai C Susini, Mol Cell Endocrinol 2008 286 12 230 237 10.1016/j.mce.2008.02. 002 18359151
48. The selective estrogen receptor modulator 4-hydroxy tamoxifen induces G1 arrest and apoptosis of multiple myeloma cell lines. J Gauduchon F Gouilleux S Maillard V Marsaud MJ Renoir B Sola, Ann N Y Acad Sci 2003 1010 321 325 10.1196/annals.1299.057 15033743
49. Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. H Hata H Matsuzaki M Takeya M Yoshida T Sonoki A Nagasaki N Kuribayashi F Kawano K Takatsuki, Blood 1995 86 5 1939 1945 7544648
50. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. J Guillermet N Saint-Laurent P Rochaix O Cuvillier T Levade AV Schally L Pradayrol L Buscail C Susini C Bousquet, Proc Natl Acad Sci USA 2003 100 1 155 160 12490654 10.1073/pnas.0136771100
51. Multiple opioid receptors on immune cells modulate intracellular signaling. BM Sharp, Brain Behav Immun 2006 20 1 9 14 10.1016/j.bbi.2005.02.002 16364815
52. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. M Pfeiffer T Koch H Schroder M Laugsch V Hollt S Schulz, J Biol Chem 2002 277 22 19762 19772 10.1074/jbc.M110373200 11896051
53. Identification and characterization of opioid and somatostatin binding sites in the opossum kidney (OK) cell line and their effect on growth. A Hatzoglou E Bakogeorgou E Papakonstanti C Stournaras DS Emmanouel E Castanas, J Cell Biochem 1996 63 4 410 421 10.1002/(SICI)1097-4644(19961215)63:4<410:: AID-JCB3>3.0.CO;2-W 8978457 (Pubitemid 27009261)
54. The inhibitory effect of opioids on HepG2 cells is mediated via interaction with somatostatin receptors. G Notas M Kampa AP Nifli K Xidakis D Papasava K Thermos E Kouroumalis E Castanas, Eur J Pharmacol 2007 555 1 1 7 10.1016/j.ejphar.2006.10.018 17113072